Alessandra Cesano

Alessandra Cesano

UNVERIFIED PROFILE

Are you Alessandra Cesano?   Register this Author

Register author
Alessandra Cesano

Alessandra Cesano

Publications by authors named "Alessandra Cesano"

Are you Alessandra Cesano?   Register this Author

59Publications

1531Reads

39Profile Views

Status of Immune Oncology: Challenges and Opportunities.

Methods Mol Biol 2020 ;2055:3-21

Cancer Diagnosis Program, National Cancer Institute, NIH, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9773-2_1DOI Listing
January 2020

Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.

J Immunother Cancer 2016 15;4:76. Epub 2016 Nov 15.

National Cancer Institute, Cancer Diagnosis Program, DCTD, National Institutes of Health, 9609 Medical Center Drive, Bethesda, 20892 MD USA ; Adaptive Biotechnologies, Inc, 1551 Eastlake Ave. E, Seattle, WA 98102 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-016-0178-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109744PMC
February 2018

Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.

Biomedicines 2018 Feb 2;6(1). Epub 2018 Feb 2.

NanoString, Inc., Seattle, WA 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biomedicines6010014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874671PMC
February 2018

Insights into acute myeloid leukemia via single cell network profiling.

Clin Lab Int 2010 Feb-Mar;34(1):12-15

201 Gateway Blvd., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696776PMC
January 2016

nCounter(®) PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA).

J Immunother Cancer 2015 15;3:42. Epub 2015 Dec 15.

NanoString Technologies, Inc., Seattle, WA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0088-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678588PMC
December 2015

Immune monitoring technology primer: Single Cell Network Profiling (SCNP).

J Immunother Cancer 2015 18;3:34. Epub 2015 Aug 18.

AC Consulting, Redwood Shores, CA 94065 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-015-0075-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539662PMC
August 2015

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Cytometry B Clin Cytom 2014 Nov 16;86(6):383-96. Epub 2013 Sep 16.

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21125DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922007PMC
November 2014

Immune system functional pathway analysis using single cell network profiling (SCNP): a novel tool in cancer immunotherapy.

Methods Mol Biol 2014 ;1102:583-99

Nodality, Inc., South San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-62703-727-3_31DOI Listing
June 2014

Age-related changes of healthy bone marrow cell signaling in response to growth factors provide insight into low risk MDS.

Cytometry B Clin Cytom 2013 Aug 20. Epub 2013 Aug 20.

The University of Texas M. D. Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cytob.21125DOI Listing
August 2013

Single cell network profiling assay in bladder cancer.

Cytometry A 2013 Apr 8;83(4):386-95. Epub 2013 Jan 8.

Research, Nodality, Inc., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.a.22244DOI Listing
April 2013

Applications of multiparametric flow cytometry: providing new insights into biology to bridge the gap between research discovery and clinical application.

Cytometry A 2012 Sep 21;81(9):732-3. Epub 2012 Jun 21.

Nodality, Inc., 170 Harbor Way, Suite 200, South San Francisco, California 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.a.22087DOI Listing
September 2012

Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.

Leuk Res 2012 Jul 21;36(7):900-4. Epub 2012 Apr 21.

Department of Research, Nodality Inc, South San Francisco, CA, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2012.02.022DOI Listing
July 2012

Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.

Mol Med 2011 11;17(7-8):854-62. Epub 2011 Mar 11.

Division of Experimental Therapeutics, Monter Cancer Center and the Feinstein Institute, Hofstra University School of Medicine, Lake Success, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2119/molmed.2010.00240DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3146606PMC
December 2011

Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease.

Autoimmunity 2010 Nov;43(7):550-9

Nodality, Inc., 201 Gateway Boulevard, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/08916931003674774DOI Listing
November 2010

Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications.

Best Pract Res Clin Haematol 2010 Sep 10;23(3):319-31. Epub 2010 Nov 10.

Nodality Inc., 201 Gateway Blvd., South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2010.07.002DOI Listing
September 2010

Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy.

Clin Cancer Res 2010 Jul 4;16(14):3721-33. Epub 2010 Jun 4.

Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385931PMC
July 2010

Single cell network profiling (SCNP): mapping drug and target interactions.

Assay Drug Dev Technol 2010 Jun;8(3):321-43

Nodality Inc., South San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/adt.2009.0251
Publisher Site
http://dx.doi.org/10.1089/adt.2009.0251DOI Listing
June 2010

Patient-specific classifications of human malignant disease.

Curr Opin Mol Ther 2009 Jun;11(3):252-9

Nodality Inc, South San Francisco, CA 94080, USA.

View Article

Download full-text PDF

Source
June 2009

Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.

J Clin Oncol 2006 Nov 30;24(33):5194-200. Epub 2006 Oct 30.

Premiere Oncology, John Wayne Cancer Institute, St John's Health Center, Santa Monica, CA 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.1152DOI Listing
November 2006

Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers.

Clin Pharmacol Ther 2006 Jun;79(6):558-69

Department of Pharmacokinetics, Clinical Pharmacology, and Regulatory Affairs, Amgen Inc., Thousand Oaks, and Quintiles Phase I Unit, Lenexa, CA 91320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clpt.2006.02.011DOI Listing
June 2006

Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

Clin Cancer Res 2004 Aug;10(16):5327-34

Division of Hematology and Oncology, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-04-0294DOI Listing
August 2004

Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.

J Clin Oncol 2003 Aug 1;21(16):3051-9. Epub 2003 Jul 1.

Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Weill Medical College of Cornell University and New York Presbyterian Hospital, 520 East 70th Street, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.01.082DOI Listing
August 2003

CD22-directed monoclonal antibody therapy for lymphoma.

Semin Oncol 2003 Aug;30(4):457-64

Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0093-7754(03)00240-9DOI Listing
August 2003

CD22 as a target of passive immunotherapy.

Semin Oncol 2003 Apr;30(2):253-7

Amgen Inc, Thousand Oaks, CA 91320, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/sonc.2003.50057DOI Listing
April 2003